Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Marius RingelsteinIlya AyzenbergGero LindenblattKatinka FischerAnna GahlenGiovanni NoviHelen Hayward-KönneckeSven SchipplingPaulus S RommerBarbara KornekTobias ZrzavyDamien BiottiJonathan CironBertrand AudoinAchim BertheleKatrin GiglhuberHelene ZephirTania KümpfelRobert BergerJoachim RötherVivien HäußlerJan-Patrick StellmannDaniel WhittamAnu JacobMarkus KraemerAntoine GueguenRomain DeschampsAntonios BayasMartin W HümmertCorinna TrebstAxel HaarmannSven JariusBrigitte WildemannMatthias GrotheNadja SiebertKlemens RuprechtFriedemann PaulNicolas CollonguesRomain MarignierMichael LevyMichael KarenfortMichael DeppePhilipp AlbrechtKerstin HellwigRalf GoldHans-Peter HartungSven G MeuthIngo KleiterOrhan Aktasnull nullPublished in: Neurology(R) neuroimmunology & neuroinflammation (2021)
This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and AQP4-IgG+ NMOSD.